Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTX Context Therapeutics	$0.66 +3.7%	$0.69	$0.49 ▼ $2.75	$57.43M	1.88	273,594 shs	117,172 shs
DRUG Bright Minds Biosciences	$28.30 +1.0%	$29.00	$0.93 ▼ $79.02	$199.84M	-6.01	829,088 shs	18,963 shs
FHTX Foghorn Therapeutics	$5.16 +4.2%	$4.43	$2.94 ▼ $10.25	$285.95M	3.05	143,021 shs	80,445 shs
MBX MBX Biosciences	$12.48 +1.2%	$11.43	$4.81 ▼ $27.50	$416.96M	N/A	258,561 shs	92,284 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTX Context Therapeutics	0.00%	-0.79%	+18.75%	+9.33%	-63.41%
DRUG Bright Minds Biosciences	0.00%	+21.62%	+1.76%	-11.67%	+2,544.86%
FHTX Foghorn Therapeutics	0.00%	+6.61%	+25.24%	+50.00%	-8.19%
MBX MBX Biosciences	0.00%	+16.05%	+5.19%	+106.54%	+1,247,499,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNTX Context Therapeutics	3.0015 of 5 stars	3.6	4.0	0.6	1.7	1.3
DRUG Bright Minds Biosciences	2.8727 of 5 stars	3.6	3.0	2.9	2.5	0.0
FHTX Foghorn Therapeutics	1.8247 of 5 stars	3.6	0.0	2.0	1.7	0.6
MBX MBX Biosciences	3.2526 of 5 stars	3.5	0.0	3.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTX Context Therapeutics	3.17	Buy	$5.50	739.69% Upside
DRUG Bright Minds Biosciences	3.13	Buy	$83.25	194.17% Upside
FHTX Foghorn Therapeutics	3.13	Buy	$12.13	134.98% Upside
MBX MBX Biosciences	3.00	Buy	$37.50	200.60% Upside

Current Analyst Ratings Breakdown

Latest CNTX, DRUG, FHTX, and MBX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
6/26/2025	CNTX Context Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$4.50 ➝ $4.00
5/21/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/15/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
5/14/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	DRUG Bright Minds Biosciences	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/13/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	DRUG Bright Minds Biosciences	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/8/2025	CNTX Context Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
5/7/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
4/30/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	$1.27 per share	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$0.92 per share	N/A
FHTX Foghorn Therapeutics	$22.60M	12.73	N/A	N/A	($0.82) per share	-6.29
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTX Context Therapeutics	-$26.73M	-$0.31	N/A	N/A	N/A	N/A	-29.78%	-29.08%	8/6/2025 (Estimated)
DRUG Bright Minds Biosciences	-$2.06M	-$0.36	N/A	N/A	N/A	N/A	-14.56%	-14.29%	8/13/2025 (Estimated)
FHTX Foghorn Therapeutics	-$86.62M	-$1.36	N/A	N/A	N/A	-342.23%	N/A	-27.28%	8/6/2025 (Estimated)
MBX MBX Biosciences	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest CNTX, DRUG, FHTX, and MBX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q2 2025	DRUG Bright Minds Biosciences	-$0.39	-$0.29	+$0.10	-$0.29	N/A	N/A
5/14/2025	Q1 2025	CNTX Context Therapeutics	-$0.05	-$0.05	N/A	-$0.05	N/A	N/A
5/14/2025	Q1 2025	FHTX Foghorn Therapeutics	-$0.30	-$0.30	N/A	-$0.30	$4.96 million	$5.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTX Context Therapeutics	N/A	48.81	48.81
DRUG Bright Minds Biosciences	N/A	126.01	126.01
FHTX Foghorn Therapeutics	N/A	3.16	3.16
MBX MBX Biosciences	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTX Context Therapeutics	14.03%
DRUG Bright Minds Biosciences	40.52%
FHTX Foghorn Therapeutics	61.55%
MBX MBX Biosciences	N/A

Insider Ownership

Company	Insider Ownership
CNTX Context Therapeutics	2.80%
DRUG Bright Minds Biosciences	42.66%
FHTX Foghorn Therapeutics	7.58%
MBX MBX Biosciences	52.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTX Context Therapeutics	7	89.70 million	87.19 million	Not Optionable
DRUG Bright Minds Biosciences	N/A	7.04 million	4.04 million	Not Optionable
FHTX Foghorn Therapeutics	120	55.74 million	51.52 million	Optionable
MBX MBX Biosciences	36	33.42 million	N/A	N/A

CNTX, DRUG, FHTX, and MBX Headlines

Recent News About These Companies

50,000 Shares in MBX Biosciences, Inc. (NYSE:MBX) Bought by Aaron Wealth Advisors LLC

July 4 at 5:04 AM | marketbeat.com

MBX Biosciences, Inc. (NYSE:MBX) Receives $37.50 Average Target Price from Analysts

June 27, 2025 | americanbankingnews.com

MBX Biosciences Inc Executives - Morningstar

June 25, 2025 | morningstar.comM

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development - Morningstar

June 24, 2025 | morningstar.comM

MBX Biosciences Inc Chart - Morningstar

June 24, 2025 | morningstar.comM

MBX Biosciences, Inc. (NYSE:MBX) Given Average Rating of "Buy" by Analysts

June 24, 2025 | marketbeat.com

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

June 23, 2025 | globenewswire.com

MBX Biosciences Submits IND for Obesity Treatment

June 16, 2025 | tipranks.com

MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

June 16, 2025 | globenewswire.com

MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

June 10, 2025 | globenewswire.com

mbx biosciences announces board changes and director elections

June 7, 2025 | uk.investing.com

MBX Biosciences: Consider Peptide Developer With GLP Drugs As A Speculative Buy

May 31, 2025 | seekingalpha.com

MBX Biosciences to Participate in June Investor Conferences

May 20, 2025 | globenewswire.com

MBX Biosciences, Inc.: Strong Buy Rating Amid Promising Phase II Data and Robust Financial Position

May 13, 2025 | tipranks.com

MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 12, 2025 | globenewswire.com

FESM's Underlying Holdings Could Mean 34% Gain Potential

May 10, 2025 | nasdaq.com

Companies Like MBX Biosciences (NASDAQ:MBX) Are In A Position To Invest In Growth

April 23, 2025 | finance.yahoo.com

MBX Biosciences to Participate in Citizens and RBC May Investor Conferences

April 22, 2025 | globenewswire.com

Ascendis Pharma initiated with an Outperform at RBC Capital

April 16, 2025 | markets.businessinsider.com

JMP Securities Initiates Coverage of MBX Biosciences (MBX) with Market Outperform Recommendation

April 11, 2025 | msn.com

Ora H. Pescovitz Buys 7,693 Shares of MBX Biosciences, Inc. (NYSE:MBX) Stock

April 11, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback
By Gabriel Osorio-Mazilli | July 3, 2025
View Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
By Nathan Reiff | June 12, 2025
View Analysts Can't Get Enough of These Little-Known Biopharma Stocks
With Novo Nordisk's CEO Out, Wall Street Wants an American Leader
By Leo Miller | June 7, 2025
View With Novo Nordisk's CEO Out, Wall Street Wants an American Leader
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
By Leo Miller | June 28, 2025
View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA
By Leo Miller | June 12, 2025
View IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA

CNTX, DRUG, FHTX, and MBX Company Descriptions

Context Therapeutics NASDAQ:CNTX

$0.66 +0.02 (+3.67%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$0.65 0.00 (-0.46%)

As of 07/3/2025 04:58 PM Eastern

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Bright Minds Biosciences NASDAQ:DRUG

$28.30 +0.29 (+1.04%)

Closing price 07/3/2025 03:27 PM Eastern

Extended Trading

$27.00 -1.30 (-4.59%)

As of 07/3/2025 04:11 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Foghorn Therapeutics NASDAQ:FHTX

$5.16 +0.21 (+4.24%)

As of 07/3/2025 01:04 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

MBX Biosciences NYSE:MBX

$12.48 +0.15 (+1.18%)

As of 07/3/2025 01:04 PM Eastern

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time